Vycellix Platform: VY-X
Amplifying Effector Cell Potency for Enhanced Serial Killing
VY-X is a novel small non-coding RNA construct which increases the efficacy of cytotoxic cellular therapies. VY-X increases the density/load of perforin and granzyme B in cytotoxic effector cells, resulting in higher serial killing including faster “time-to-next-kill”. Potential applications include: 1) ex vivo treatment of cells before adoptive transfer; and 2) in vivo administration as an adjuvant with T cell and/or NK cell therapies/engagers, or as consolidation/maintenance monotherapy following complete response to boost endogenous effector cells to target minimal residual disease.